Status: Recruiting
Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy
This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the graft versus tumor effect, while minimizing acute and chronic graft versus host disease (GVHD).
Participants needed: 120
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Wake Forest University Health SciencesUpdated: Jul 13, 2026Locations: 1
Eligibility criteria
Informed consent and HIPAA authorization for release of personal health informat... [+4]
Recipient only (applies only to haplo-identical and MRD HCT recipients; not requ... [+2]